Dattatri Rohini, Garg Rakesh, Ray Mukur Dipi
Department of Onco-Anaesthesia and Palliative Medicine, Dr. BRAIRCH, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
Saudi J Anaesth. 2019 Apr-Jun;13(2):131-135. doi: 10.4103/sja.SJA_545_18.
Cytoreductive surgeries (CRSs) are the common management modality for advanced cancers. The perioperative period is impacted by major surgical resection and its associated effects. The surgical morbidity is further enhanced when the resection of abdominal and thoracic cavity is required simultaneously. It is added on by the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) and hyperthermic intrathoracic chemotherapy (HITHOC). These procedures are technically challenging with potential for high perioperative morbidity and mortality. We report a case of 56-year-old female diagnosed with carcinoma ovary with pleural metastases and malignant right pleural effusion and scheduled for CRS with HIPEC together with HITHOC.
肿瘤细胞减灭术（CRS）是晚期癌症的常见治疗方式。围手术期受到大型手术切除及其相关影响的冲击。当需要同时切除腹腔和胸腔时，手术发病率会进一步增加。热灌注腹腔化疗（HIPEC）和热灌注胸腔化疗（HITHOC）的影响也会加剧这种情况。这些手术在技术上具有挑战性，围手术期发病率和死亡率较高。我们报告一例56岁女性，诊断为卵巢癌伴胸膜转移及右侧恶性胸腔积液，计划行CRS联合HIPEC及HITHOC。
